Tue Jul 15 03:20:00 UTC 2025: **Summary:**
Anthem Biosciences, a contract research, development, and manufacturing organization (CRDMO), is launching an IPO to raise ₹3,395 crore, which will dilute the promoter group’s stake. While the company’s revenue and profit have increased, it faces risks due to geographical and client concentration. The company’s P/E ratio is high compared to its peers, making the IPO suitable for high-risk investors.
**News Article:**
**Anthem Biosciences Launches ₹3,395 Crore IPO Amidst Growth and Risk**
**Bengaluru:** Anthem Biosciences, a contract research, development, and manufacturing organization (CRDMO), has announced its initial public offering (IPO) to raise ₹3,395 crore. The IPO will involve a dilution of the promoter group’s stake in the company.
The company has demonstrated strong financial performance, with revenue and profit showing growth. However, analysts point out that Anthem Biosciences faces potential risks due to its concentration of clients and geographical presence.
The IPO’s pricing reflects a high price-to-earnings (P/E) ratio compared to its competitors in the CRDMO sector. This may make the offering more attractive to investors with a higher risk tolerance who are willing to bet on the company’s future growth potential despite existing concentration risks.
The IPO is expected to generate significant interest in the market as Anthem Biosciences seeks to expand its operations and capitalize on the growing demand for CRDMO services.
First Piper 